| Similar Articles |
 |
The Motley Fool September 8, 2006 Brian Lawler |
Ligand's Drug Sale For the pharmaceutical's marketed drugs, everything must go. Investors, take note.  |
The Motley Fool April 4, 2007 Brian Lawler |
Companies That Pay Out ... and Drop Here is an explanation of why a stock price falls after a large one-time dividend payout.  |
The Motley Fool May 7, 2008 Brian Lawler |
PDL Delivers a Dividend The drugmaker's investors get a hefty payout.  |
The Motley Fool November 13, 2006 Brian Lawler |
King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.  |
The Motley Fool April 14, 2008 Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.  |
The Motley Fool March 5, 2008 Brian Lawler |
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.  |
The Motley Fool March 26, 2007 Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.  |
The Motley Fool June 23, 2008 Brian Lawler |
Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta.  |
The Motley Fool August 6, 2004 Zeke Ashton |
Are Biotechs Worth the Risk? Even when their drugs are doing well, companies in this industry don't necessarily yield big rewards for investors.  |
The Motley Fool September 24, 2007 Brian Lawler |
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note.  |
The Motley Fool April 28, 2011 Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.  |
The Motley Fool March 3, 2009 Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.  |
The Motley Fool August 3, 2004 Charly Travers |
Black Cloud Over Ligand The pharmaceuticals company misses estimates and loses an auditor. Many investors are going to be skeptical about whether guidance will be met.  |
The Motley Fool April 18, 2007 Rick Aristotle Munarriz |
A Funky New Topping at Domino's Domino's will be sending its shareholders a special one-time dividend next month. But remember that there's no free lunch.  |
The Motley Fool December 7, 2011 Dan Caplinger |
Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders.  |
The Motley Fool November 2, 2006 Rich Duprey |
Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.  |
The Motley Fool June 27, 2008 |
What's a Dividend? Some companies repay your investment with cold, hard cash.  |
The Motley Fool February 17, 2005 |
What's a Dividend? A dividend is a portion of a company's earnings that the firm pays out to its shareholders.  |
The Motley Fool May 29, 2008 Brian Lawler |
Ligand Loses, for Now The FDA sends Ligand Pharmaceutical this message: approval unlikely, try again later.  |
The Motley Fool March 25, 2009 Brian Orelli |
The FDA Leaves Pfizer in the Waiting Room The EU loves its new osteoporosis drug, but what about the U.S.?  |
The Motley Fool August 13, 2008 Selena Maranjian |
Look Beyond the Headlines For dividend investors, the recent news that Stanley Works hiked its dividend for the 41st straight year sounds downright enticing. But the headlines alone don't tell the whole story. Read on for more.  |
The Motley Fool December 14, 2007 Claire Stephanic |
The Best Returns Possible High yield + low payout ratio = superior long-term investment.  |
The Motley Fool July 30, 2004 Ben McClure |
AT&T's Kindest Cut A big dividend cut at Ma Bell is long overdue. Without it, shareholders could be headed for even more trouble.  |
The Motley Fool August 19, 2011 Cindy Johnson |
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them?  |
The Motley Fool March 2, 2009 Dan Caplinger |
7 Stocks With Dividends That Should Survive Don't get caught by a dividend cut.  |
The Motley Fool June 17, 2008 Tom Hutchinson |
Will Bank of America Cut the Dividend? What costs will Bank of America endure to keep its payout intact?  |
The Motley Fool May 15, 2007 Rich Duprey |
Eisai Doles Out Tough Medicine The Japanese pharmaceutical company wins a patent infringement decision regarding its heartburn treatment. Investors, take note.  |
The Motley Fool February 5, 2009 Brian Orelli |
Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable.  |
The Motley Fool June 8, 2007 Joe Magyer |
Avoid the Next Dividend Implosion Dividend stocks may have a reputation of being safe or stodgy, but sometimes they're anything but. Here are three keys to help you spot a dividend cut from a mile away.  |
The Motley Fool August 25, 2008 Ilan Moscovitz |
The Next 2 Dividend Blowups? Nearly 100 companies cut their dividends during the second quarter, the biggest quarterly decline since 1991. Who might be next?  |
The Motley Fool September 18, 2009 Dan Caplinger |
These Stocks Are Growing in All the Right Ways These good dividend stocks have the earnings to back up their payouts: Monsanto... McDonald's... Microsoft... Lockheed Martin... CSX... IBM...  |
The Motley Fool February 8, 2010 Selena Maranjian |
Good News About the Worst Year It's over. Remember, the overall trend of the market is up. When stocks of good, healthy, and growing companies get beaten down, they're likely to regain their footing.  |
The Motley Fool January 24, 2008 Selena Maranjian |
Which Dividends Can You Count On? Some dividends are safe; while others are at risk.  |
The Motley Fool July 25, 2008 Dan Dzombak |
3 Stocks Hitting High Notes These stocks are bucking the trend.  |
Chemistry World November 7, 2014 Katrina Kramer |
Stressed ligands switch catalysis selectivity Researchers have discovered that enantioselectivity in palladium-catalyzed reactions depends on the ligand's intramolecular strain.  |